middle.news
FDA Greenlights DAYBUE STIX Powder for Rett Syndrome, Boosting Neuren Royalties
9:13am on Monday 15th of December, 2025 AEDT
•
Pharmaceuticals
Read Story
FDA Greenlights DAYBUE STIX Powder for Rett Syndrome, Boosting Neuren Royalties
9:13am on Monday 15th of December, 2025 AEDT
Key Points
FDA approves DAYBUE STIX, a dye- and preservative-free powder formulation
DAYBUE STIX offers flexible dosing and taste options for Rett syndrome patients
Both DAYBUE and DAYBUE STIX are the only FDA-approved Rett syndrome treatments
Neuren to receive royalties on net sales and potential milestone payments
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE